We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+18.09%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$151M
AUM Growth
–
Cap. Flow
+$142M
Cap. Flow
% of AUM
94.05%
Top 10 Holdings %
Top 10 Hldgs %
64.81%
Holding
17
New
17
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coherus Oncology
CHRS
|
+$10.7M |
| 2 |
Supernus Pharmaceuticals
SUPN
|
+$10M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$9.37M |
| 4 |
Cencora
COR
|
+$9.3M |
| 5 |
Cigna
CI
|
+$9.22M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
KP
TCM
SAAM
PAA
PC
BOCH
GIP
PC
HealthInvest Partners's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for HealthInvest Partners, which disclosed 17 positions worth $151M. Its ten largest holdings account for 65% of the portfolio.
Its largest position is Coherus Oncology: 600,000 shares worth $10.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- HealthInvest Partners's largest Q4 2020 buy was Coherus Oncology: 600,000 shares worth $10.4M.
- HealthInvest Partners's ten largest holdings make up 65% of its $151M portfolio in Q4 2020.
- HealthInvest Partners disclosed 17 positions in Q4 2020, its first 13F filing on record.
Based on HealthInvest Partners's 13F filing for Q4 2020, filed 5 Feb 2021.